Boniver R
Arzneimittelforschung. 1978;28(10):1800-4.
The antivertiginous properties of 1-[bis(p-fluorophenyl)-methyl]-4-cinnamylpiperazine (flunarizine, R 14 950) were evaluated in three consecutive studies -- two open and one double-blind -- in a total of 99 patients showing definite vertigo. Dosage was two tablets (= 20 mg) t.i.d. for three days in Study I (50 patients), 20 mg t.i.d. for two months in Study II (31 patients), and weekly decreasing doses of four, three, two and one (maintenance) tablets of flunarizine or placebo for three months in Study III (9/18 patients with vertigo of recent origin). Improvement of vertigo was significant both objectively and subjectively in Studies I and II. In Study III, objective tests were always clearly in favour of flunarizine, but subjectively, flunarizine was superior only by month two. Vertigo of vascular origin seemed to be a preferential indication for flunarizine treatment. No major side-effects were found in these studies.
在三项连续的研究中（两项开放性研究和一项双盲研究），对1-[双（对氟苯基）-甲基]-4-肉桂基哌嗪（氟桂利嗪，R 14 950）的抗眩晕特性进行了评估，共有99例表现出明确眩晕症状的患者参与。在研究I（50例患者）中，剂量为每日三次，每次两片（=20毫克），共服用三天；在研究II（31例患者）中，剂量为每日三次，每次20毫克，服用两个月；在研究III（9/18例近期发生眩晕的患者）中，每周递减剂量服用氟桂利嗪或安慰剂，剂量分别为四片、三片、两片和一片（维持量），共服用三个月。在研究I和II中，眩晕症状在客观和主观方面均有显著改善。在研究III中，客观测试结果始终明显有利于氟桂利嗪，但在主观方面，仅在第二个月时氟桂利嗪表现更优。血管源性眩晕似乎是氟桂利嗪治疗的优先适应证。在这些研究中未发现重大副作用。
